Cristina G. Arriens

Cristina G. Arriens

Rheumatology

825 N.E. 13th St.
Oklahoma City, OK 73104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Enpatoran: promising mechanism, pharmacodynamic challenge.

Enpatoran: promising mechanism, pharmacodynamic challenge.

Journal: The Lancet. Rheumatology

Published: January 16, 2026

Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus.

Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus.

Journal: Annals of the rheumatic diseases

Published: December 04, 2025

Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity.

Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity.

Journal: Arthritis care & research

Published: November 13, 2025

Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.

Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.

Journal: Annals of the rheumatic diseases

Published: September 23, 2025

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 05, 2025

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 05, 2025

A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus.

A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 15, 2025

Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.

Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.

Journal: Advances in therapy

Published: March 19, 2025

Serum NF-κB-Regulated Biomarkers of Proliferative Lupus Nephritis.

Serum NF-κB-Regulated Biomarkers of Proliferative Lupus Nephritis.

Journal: Glomerular diseases

Published: December 31, 2024

Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.

Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.

Journal: JCI insight

Published: February 29, 2024

Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype.

Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype.

Journal: Frontiers in immunology

Published: November 15, 2023

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE.

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE.

Journal: Lupus science & medicine

Published: April 21, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026